摘要:
La présente invention concerne des produits constitués d'inhibiteurs de phosphodiestérases et/ou d'activateurs d'adénylate cyclase et/ou de guanylate cyclase pour une utilisation dans le traitement de réhabilitation de la vision chez une personne aveugle ou atteinte de cécité légale, la cécité étant liée à la dégénérescence et/ou au dysfonctionnement des photorécepteurs.
摘要:
It is disclosed a composition of one or more active compounds belonging to the group of neonicotinoids suitable to be administered to humans and used to kill free-living blood feeding ectoparasites including ectoparasitic arthropods. The group of neonicotinoids includes imidacloprid, thiacloprid, acetamiprid, thiamethoxam, nitenpyram, and/or its subgroups e.g. nitroguanidines such as clothianidine. Neonicotinoids comprising compositions can be used to kill free-living blood feeding ectoparasites, shortly after feeding on a human host, and in this way prevent such ectoparasites from surviving to pass on pathogens to other humans or pathogen reservoir hosts.
摘要:
The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
摘要:
Methods for regulating the formation of a sulfilimine crosslink in a subject by administering a sulfilimine crosslink modulator are disclosed The sulfilimine modulator may inhibit or create a sulfilimine crosslink and maybe useful for treating a disease, such as cancer The sulfilimine crosslink may be between two or more peptides
摘要:
The present invention is directed to the use of the combination of the peptide compounds Asp-Val-Ala-His-Gly-lle-Leu-Asn-Glu-Ala-Tyr-Arg-Lys-Val-Leu-Asp-Gin-Leu-Ser-Ala-Gly-Lys-His-Leu-Gln-Ser-Leu-Val-Ala and His-Ser-Asp-Gly-lle-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu- Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH 2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
摘要:
The present invention is directed to the use of the peptide compound Pyr-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH 2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH 2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
摘要:
The present invention is directed to the use of the peptide compound Lys-lle-Cys-lle-Arg-lle-Gln-lle-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Lys-lle-Cys-lle-Arg-lle-Gln-lle-Ser-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
摘要:
The present invention is directed to the use of the peptide compound Lys-Val-Leu-Pro-Val-Pro-Gln-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Lys-Val-Leu-Pro-Val-Pro-Gln-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
摘要:
The present invention is directed to the use of the peptide compound Cyclo(D-Ser-Pro-D-Val-Leu-D-Trp) as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Cyclo(D-Ser-Pro-D-Val-Leu-D-Trp) optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.